178 related articles for article (PubMed ID: 38225233)
41. TFAP4 Promotes Hepatocellular Carcinoma Invasion and Metastasis via Activating the PI3K/AKT Signaling Pathway.
Huang T; Chen QF; Chang BY; Shen LJ; Li W; Wu PH; Fan WJ
Dis Markers; 2019; 2019():7129214. PubMed ID: 31281549
[TBL] [Abstract][Full Text] [Related]
42. Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.
Bonnin M; Fares N; Testoni B; Estornes Y; Weber K; Vanbervliet B; Lefrançois L; Garcia A; Kfoury A; Pez F; Coste I; Saintigny P; Viari A; Lang K; Guey B; Hervieu V; Bancel B; Bartoch B; Durantel D; Renno T; Merle P; Lebecque S
J Hepatol; 2019 Oct; 71(4):763-772. PubMed ID: 31220470
[TBL] [Abstract][Full Text] [Related]
43. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma.
Zhang J; Cheng J; Zeng Z; Wang Y; Li X; Xie Q; Jia J; Yan Y; Guo Z; Gao J; Yao M; Chen X; Lu F
Oncotarget; 2015 Dec; 6(39):42040-52. PubMed ID: 26547929
[TBL] [Abstract][Full Text] [Related]
45. DNASE1L3 inhibits hepatocellular carcinoma by delaying cell cycle progression through CDK2.
Sun J; Wang X; Shen Q; Wang M; Chen S; Zhang X; Huang Y; Zhang Z; Li W; Yuan Y; Huang Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1187-1202. PubMed ID: 36327092
[TBL] [Abstract][Full Text] [Related]
46. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.
Moeini A; Torrecilla S; Tovar V; Montironi C; Andreu-Oller C; Peix J; Higuera M; Pfister D; Ramadori P; Pinyol R; Solé M; Heikenwälder M; Friedman SL; Sia D; Llovet JM
Gastroenterology; 2019 Nov; 157(5):1383-1397.e11. PubMed ID: 31344396
[TBL] [Abstract][Full Text] [Related]
47. SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model.
Xu M; Wang J; Xu Z; Li R; Wang P; Shang R; Cigliano A; Ribback S; Solinas A; Pes GM; Evert K; Wang H; Song X; Zhang S; Che L; Pascale RM; Calvisi DF; Liu Q; Chen X
Cancer Res; 2019 Nov; 79(21):5563-5574. PubMed ID: 31383647
[TBL] [Abstract][Full Text] [Related]
48. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
[TBL] [Abstract][Full Text] [Related]
49. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes HCC cell invasiveness and metastasis in mice.
Li Y; Chen L; Chan TH; Liu M; Kong KL; Qiu JL; Li Y; Yuan YF; Guan XY
Gastroenterology; 2013 Jan; 144(1):179-191.e4. PubMed ID: 23022495
[TBL] [Abstract][Full Text] [Related]
50. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
51. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
[TBL] [Abstract][Full Text] [Related]
52. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
53. Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice.
Cai WY; Lin LY; Hao H; Zhang SM; Ma F; Hong XX; Zhang H; Liu QF; Ye GD; Sun GB; Liu YJ; Li SN; Xie YY; Cai JC; Li BA
Hepatology; 2017 Apr; 65(4):1206-1221. PubMed ID: 27809333
[TBL] [Abstract][Full Text] [Related]
54. Liver haploinsufficiency of RuvBL1 causes hepatic insulin resistance and enhances hepatocellular carcinoma progression.
Mello T; Materozzi M; Zanieri F; Simeone I; Ceni E; Bereshchenko O; Polvani S; Tarocchi M; Marroncini G; Nerlov C; Guasti D; Bani D; Pinzani M; Galli A
Int J Cancer; 2020 Jun; 146(12):3410-3422. PubMed ID: 31721195
[TBL] [Abstract][Full Text] [Related]
55. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract][Full Text] [Related]
56. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair.
Machida K; Tsukamoto H; Liu JC; Han YP; Govindarajan S; Lai MM; Akira S; Ou JH
Hepatology; 2010 Aug; 52(2):480-92. PubMed ID: 20683948
[TBL] [Abstract][Full Text] [Related]
57. ANT2 suppression by shRNA restores miR-636 expression, thereby downregulating Ras and inhibiting tumorigenesis of hepatocellular carcinoma.
Jang JY; Lee YS; Jeon YK; Lee K; Jang JJ; Kim CW
Exp Mol Med; 2013 Jan; 45(1):e3. PubMed ID: 23306701
[TBL] [Abstract][Full Text] [Related]
58. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
[TBL] [Abstract][Full Text] [Related]
59. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer.
Tao J; Ji J; Li X; Ding N; Wu H; Liu Y; Wang XW; Calvisi DF; Song G; Chen X
Oncotarget; 2015 Mar; 6(9):6977-88. PubMed ID: 25762642
[TBL] [Abstract][Full Text] [Related]
60. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
